1. Clinical & Scientific Overview
Salmeterol Xinafoate (in Fixed-Dose Combination with Fluticasone Propionate) (TIP-MED-000168, Reference Code [9.4]) is classified under
Respiratory, Asthma, COPD & Allergy Medicines (Ch 09) as a Slow-Onset Long-Acting Beta-2 Adrenergic Agonist (LABA; 12-Hour Bronchodilator with Slow 15–30 Minute Onset).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Seroflo (Cipla), Foracort (Cipla)
Seroflo pMDI Inhaler: Salmeterol 25 mcg + Fluticasone Propionate 125 mcg or 250 mcg per puff; Seroflo Rotacaps / Autohaler / Accuhaler (DPI): Salmeterol 50 mcg + Fluticasone Propionate 100 mcg, 250 mcg, or 500 mcg
3. Mechanism of Action & Pharmacodynamics
Slow-Onset Long-Acting Beta-2 Adrenergic Agonist (LABA; 12-Hour Bronchodilator with Slow 15–30 Minute Onset) acting on target receptor/enzyme pathways in Respiratory, Asthma, COPD & Allergy Medicines (Ch 09): clinical efficacy is mediated via Slow-Onset Long-Acting Beta-2 Adrenergic Agonist (LABA; 12-Hour Bronchodilator with Slow 15–30 Minute Onset) for Regular maintenance controller therapy for persistent Bronchial Asthma and severe COPD with history of repeated exacerbations..
4. Therapeutic Indications & Evidence-Supported Uses
- Regular maintenance controller therapy for persistent Bronchial Asthma and severe COPD with history of repeated exacerbations
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: pMDI: 2 puffs twice daily (every 12 hours, delivering 50 mcg salmeterol/dose). Rotacap / Accuhaler DPI: 1 capsule/blister (50 mcg salmeterol) twice daily (every 12 hours). Maximum dose: 50 mcg Salmeterol twice daily! Follow physician prescription.
Administration & Meal Timing: Inhaled: Independent of food; rinse mouth and spit after every dose. | Strictly twice daily (every 12 hours: morning and night).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: No dose adjustment needed. Hepatic: Both salmeterol and fluticasone undergo extensive hepatic CYP3A4 clearance; monitor closely in moderate-to-severe liver disease.
Renal: No dose adjustment needed. Hepatic: Both salmeterol and fluticasone undergo extensive hepatic CYP3A4 clearance; monitor closely in moderate-to-severe liver disease.
Renal: No dose adjustment needed. Hepatic: Both salmeterol and fluticasone undergo extensive hepatic CYP3A4 clearance; monitor closely in moderate-to-severe liver disease.
7. Contraindications, Precautions & High-Risk Warnings
- CRITICAL DIFFERENCE FROM FORMOTEROL (FORACORT): Salmeterol has a SLOW onset of action (takes 15 to 30 minutes to begin opening airways, peaking at 2–3 hours)! Therefore, Seroflo MUST NEVER BE USED AS AN ACUTE RESCUE RELIEVER during a sudden asthma attack! Patients using Seroflo MUST always carry a separate fast-acting reliever inhaler (such as Salbutamol [Asthalin]) for sudden breathlessness! Never exceed twice-daily dosing.
Key Clinical Precautions: Renal: No dose adjustment needed. Hepatic: Both salmeterol and fluticasone undergo extensive hepatic CYP3A4 clearance; monitor closely in moderate-to-severe liver disease.
8. Adverse Effects Profile
- Oropharyngeal candidiasis (thrush) and hoarseness of voice (fluticasone has high topical potency and throat deposition if a spacer and mouth rinse are not used), fine tremor, palpitations, headache, muscle cramps.
- Increased incidence of bacterial Pneumonia in elderly COPD patients (particularly with the high 500 mcg fluticasone strength), systemic steroid effects (adrenal suppression, cataracts, osteoporosis), hypokalaemia, arrhythmias in IHD patients, paradoxical bronchospasm.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Potent CYP3A4 Inhibitors (Ritonavir, Ketoconazole, Itraconazole, Clarithromycin): STRICTLY AVOID! Ritonavir and itraconazole increase plasma Fluticasone levels >100-fold (causing severe Cushing's syndrome and adrenal crisis) and increase Salmeterol levels (causing QTc prolongation and ventricular arrhythmias)
- Non-selective beta-blockers antagonise salmeterol
- Diuretics/theophylline increase hypokalaemia
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: 1. Warn every patient on Seroflo: 'Seroflo is your slow-acting 12-hour daily shield—it takes 20 minutes to start working, so NEVER puff extra Seroflo during a sudden breathless attack! Keep your blue Asthalin inhaler handy for sudden rescue.' 2. Note that pMDI requires 2 puffs to deliver 50 mcg salmeterol (with a 30–60 second pause between puff 1 and puff 2), whereas Rotacaps require 1 capsule inside the Rotahaler. 3. Always rinse mouth, gargle, and spit water after every use!
- Meal & Clock Timing Instruction: Inhaled: Independent of food; rinse mouth and spit after every dose. (Strictly twice daily (every 12 hours: morning and night).)
- Missed Dose Protocol: Take the next scheduled dose at the normal time; never take extra puffs of Seroflo for acute breathlessness.
- Geriatric Dispensing Pearl: In elderly COPD patients using high-strength Seroflo 250 or 500, watch closely for recurrent lower respiratory infections/pneumonia, oral thrush, cataracts, and easy skin bruising; verify if the chest physician can step down steroid dose or use LAMA/LABA dual bronchodilation if eosinophils are low.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Seroflo pMDI Inhaler: Salmeterol 25 mcg + Fluticasone Propionate 125 mcg or 250 mcg per puff; Seroflo Rotacaps / Autohaler / Accuhaler (DPI): Salmeterol 50 mcg + Fluticasone Propionate 100 mcg, 250 mcg, or 500 mcg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 09 [9.4] (p. 115)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.